Liraglutide Hospital Discharge Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 273 participants.

Also called NCT01919489

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 273 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01919489
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01919489. Randomized; no masking; primary purpose treatment. Start 2014-03 (actual); primary completion 2020-08-30 (actual). Results posted on 2021-11-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Liraglutide Hospital Discharge Trial
Intervention (Drug)
Liraglutide + OADs
Intervention (Drug)
Glargine + OADs
Lead sponsor
Emory University (class: other)
Collaborator
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01919489
Content hash
37f3786b98cbd72e61f6dfe5147d247bf982828acdfd2510db6ddffdb584cc52